ArticleBMC cancer2026
High TROP-2 expression as a predictor of poor neoadjuvant chemotherapy response in luminal B breast cancer: a retrospective clinicopathological study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTrophoblast cell surface antigen 2 (TROP-2) is a type I transmembrane glycoprotein that is expressed on the cell surface. It is overexpressed in various epithelial malignancies. Due to its protumoral biological effects and its role as a target receptor for antibody-drug conjugates, TROP-2 is of particular clinical interest. This study aims to investigate the relationships between TROP-2 expression, clinicopathological parameters, and response to neoadjuvant chemotherapy in invasive breast carcinomas.
methodsTROP-2 expression was evaluated by immunohistochemically from 211 cases of invasive breast carcinoma. The H-score was used in the TROP-2 assessment. Cases with a score of 0-200 were considered low, and cases with a score above 200 were considered high TROP-2 expression.
resultsHigh TROP-2 expression was significantly associated with HER2 negativity (p = 0.019), lymph node metastasis (p = 0.016), and a poor response to neoadjuvant chemotherapy (RCB-II/III) (p = 0.01). Multivariate analysis revealed that molecular subtype, stromal tumor-infiltrating lymphocytes, and high TROP-2 expression were independent predictors of neoadjuvant chemotherapy response.
conclusionHigh TROP-2 expression was found to be associated with adverse clinicopathological parameters and poor response to neoadjuvant chemotherapy, and was identified as an independent predictive biomarker for neoadjuvant response. The lower pathological complete response rates observed in luminal B molecular subtype breast carcinomas with high TROP-2 expression suggest that TROP-2-targeting agents should be investigated more thoroughly in the neoadjuvant therapy setting, particularly in LB subtype cases. Furthermore, assessing TROP-2 expression in each case will aid in optimal patient selection for treatment and contribute to the personalization of oncological therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.